Mental Health Treatments.Therapies, drugs, and what works

OpeningThe good news, the bad news.

Mental health treatment in 2026 is more effective and more available than at any point in human history. The treatment gap — the proportion of people with diagnosable disorders who receive no treatment — remains roughly half in high-income countries, and 80%+ in low- and middle-income countries.

The good news. We have a small set of psychotherapies (CBT, DBT, ACT, IPT, EMDR, exposure therapies) and a small set of pharmacotherapies (SSRIs, SNRIs, mood stabilisers, atypical antipsychotics) with substantial evidence bases. For most common disorders — depression, anxiety, OCD, PTSD, bipolar disorder — a 60–70% response rate to first-line treatment is achievable.

The bad news. Treatment-resistant cases are common. Effect sizes for individual treatments are smaller than the lay public believes. The empirical evidence is contested, particularly on antidepressants. And a third of patients do not get better with available treatment. This deck covers what works, what doesn't, and what's emerging.

Chapter IThe seven major modalities.

Most empirically-supported psychotherapy comes from a handful of named approaches.

Chapter IIAaron Beck's invention.

Aaron Beck (1921–2021), Philadelphia psychiatrist, trained as a Freudian psychoanalyst. While treating depressed patients in the early 1960s, he noticed they reported automatic streams of negative thoughts ("I'm worthless," "Nothing will work out") that the psychoanalytic framework did not address directly. He developed cognitive therapy — later cognitive-behavioural therapy as it absorbed behavioural techniques — to target those thoughts.

The cognitive triad of depression: negative views of self, world, and future. The framework: identify automatic thoughts, evaluate evidence for and against them, generate alternative interpretations, test through behavioural experiments. The therapy is structured, time-limited (typically 12–20 sessions), homework-based, and explicitly taught.

The empirical record is the strongest of any psychotherapy. The 2013 Hofmann et al. meta-meta-analysis found CBT effective across depression, anxiety, OCD, PTSD, eating disorders, insomnia, chronic pain, and somatoform disorders. Effect sizes are typically moderate (Cohen's d ~0.5–0.8 for most conditions); larger for OCD and panic, smaller for major depression than originally reported.

Chapter IIIMarsha Linehan's synthesis.

Marsha Linehan (1943–) developed Dialectical Behaviour Therapy in the late 1970s and 1980s while working at the University of Washington with chronically suicidal patients — many of whom met diagnostic criteria for borderline personality disorder. Standard CBT was insufficient; pure validation was insufficient; the patients needed both.

The dialectic: change-oriented technique balanced against acceptance and validation. Linehan, who later disclosed her own history of severe mental illness and suicidality, drew explicitly on her training in Zen Buddhism for the acceptance components.

The full DBT package: weekly individual therapy, weekly group skills training (mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness), between-session phone coaching, and a therapist consultation team. The 1991 Linehan trial demonstrated reduction in suicide attempts and hospitalisations vs treatment as usual; subsequent trials have replicated for BPD and expanded the indications.

DBT skills training, the group-based component, has been adapted broadly — many of the skills are now in the public domain through workbooks and apps.

Chapter IVThe third wave.

Steven Hayes coined "third-wave" cognitive-behavioural therapy in the late 1990s — the first wave being behavioural therapy (Skinner, Wolpe), the second being cognitive (Beck, Ellis), the third being context- and acceptance-based (ACT, DBT, MBCT, FAP).

Acceptance and Commitment Therapy (always pronounced "act") rests on six processes: defusion (separating self from thoughts), acceptance, contact with the present moment, self-as-context, values clarification, committed action. The core insight: trying to eliminate unwanted thoughts and feelings often amplifies them; the alternative is acceptance combined with values-driven action despite them.

The empirical base: roughly 1,000 RCTs as of 2024. Meta-analyses show effect sizes comparable to CBT for anxiety, depression, and chronic pain. ACT is particularly suited to the chronic-disease model — chronic pain, chronic illness, persistent symptoms — where elimination is unrealistic and acceptance shifts the burden.

The relational frame theory underlying ACT is more controversial than the clinical applications.

Chapter VInterpersonal therapy.

Gerald Klerman (1928–1992) and Myrna Weissman developed Interpersonal Therapy at Yale and Harvard in the 1970s, originally as an active control condition for testing antidepressant trials. To their surprise, IPT performed competitively with imipramine in major depression. It became established as a first-line treatment.

IPT is brief (12–16 sessions), structured, and focused on four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. It does not interpret transference or work on early childhood; it works on the present life. The Klerman-Weissman manual (1984) made it transmissible.

The empirical record. IPT is one of three therapies (with CBT and behavioural activation) with the strongest depression evidence base. Adapted forms — IPT-A for adolescents, group IPT, IPT for postpartum depression — have replicated. The WHO mhGAP programme recommends IPT for global mental health scale-up because it can be delivered by trained non-specialists.

Chapter VIThe Freud lineage, modernised.

The psychoanalytic tradition was the dominant talk therapy from Freud's early-20th-century work through the 1970s. The decline came partly from inability to demonstrate efficacy in randomised trials, partly from the rise of CBT, partly from the inability to scale a four-times-a-week multi-year treatment.

The 21st-century revival has been led by short-term psychodynamic psychotherapy (STPP) — typically 16–40 sessions, manualised, transference- and pattern-focused. The Leichsenring meta-analyses (2008, 2017) showed STPP effective for depression, anxiety, and personality disorders, with effect sizes broadly comparable to CBT.

The work of Peter Fonagy and Anthony Bateman on mentalisation-based treatment (MBT), and Otto Kernberg on transference-focused psychotherapy (TFP), are the contemporary high-evidence-base derivatives. Both have demonstrated efficacy for borderline personality disorder in RCTs.

The case for psychodynamic therapy is strongest where insight into pattern is the change mechanism; the case is weaker where structured behavioural change suffices.

Chapter VIIThe system as patient.

Family therapy emerged in the 1950s–60s from multiple sources: Gregory Bateson and the Palo Alto group on schizophrenia and communication patterns; Salvador Minuchin and structural family therapy at Wiltwyck and the Philadelphia Child Guidance Clinic; Murray Bowen on multigenerational family systems.

The shared insight: many psychological problems are systemic rather than individual. The "identified patient" — usually a child or adolescent — often expresses dysfunction that originates in family dynamics. Treating the individual without addressing the system produces relapse on return home.

The strongest contemporary evidence is for adolescent eating disorders. The Maudsley family-based treatment (FBT), developed at the Maudsley Hospital in London in the 1980s, has the largest effect size of any treatment for adolescent anorexia nervosa — substantially outperforming individual therapy. The James Lock and Daniel Le Grange manualisation (2001, revised 2013) made FBT broadly transmissible.

Multisystemic therapy (MST), Functional Family Therapy (FFT), and other adapted family-based interventions have strong evidence bases for adolescent conduct problems and substance use.

Chapter VIIIThe contested treatment that worked.

Eye Movement Desensitisation and Reprocessing was developed by Francine Shapiro in 1987 after she noticed her own anxious thoughts reduced when she walked through a park making side-to-side eye movements. The protocol asks the patient to recall a traumatic memory while the therapist directs bilateral eye movements (or alternating tactile or auditory stimulation).

EMDR was greeted with substantial skepticism — the proposed mechanism (eye movements producing reprocessing of traumatic memory) lacked obvious neuroscientific basis, and the original studies were methodologically weak. By the 2010s, however, the empirical base had grown substantially, and EMDR was endorsed for PTSD by the WHO, the APA, and the UK NICE.

The "dismantling" research suggests the bilateral eye movements may be less essential than the exposure component — EMDR may be effectively a structured exposure therapy with idiosyncratic packaging. But the empirical efficacy holds. For PTSD, EMDR and prolonged exposure (PE) and cognitive processing therapy (CPT) are the three first-line trauma-focused treatments.

Chapter IXThe Prozac era.

Fluoxetine (Prozac) was approved by the FDA on 29 December 1987. Eli Lilly's chemist David Wong had synthesised it in 1972; it had been the result of a structured search for selective serotonin reuptake inhibitors. By 1990, Prozac was on the cover of Newsweek.

The SSRIs — fluoxetine, sertraline, paroxetine, citalopram, escitalopram — selectively inhibit reuptake of serotonin from the synaptic cleft, increasing synaptic serotonin. The clinical effect on depression and anxiety typically takes 4–6 weeks to develop, even though the pharmacological effect on serotonin is immediate. The mechanism by which delayed neuroadaptation produces clinical change remains incompletely understood.

Effect sizes are smaller than the lay public assumes. The Cipriani et al. 2018 Lancet meta-analysis of 522 trials showed all 21 antidepressants outperformed placebo, but the difference was modest (response rates ~50% on drug vs ~35% on placebo for major depression). For severe depression the effects are clearer; for mild-to-moderate the placebo response is large and the marginal benefit of medication is debated.

The withdrawal-syndrome literature, long underplayed, has been revised upward — discontinuation symptoms can be severe and prolonged, particularly with paroxetine and venlafaxine.

Chapter XBeyond serotonin.

SNRIs (serotonin-norepinephrine reuptake inhibitors) — venlafaxine (Effexor, 1993), duloxetine (Cymbalta, 2004) — work on both serotonin and norepinephrine systems. Modestly more effective than SSRIs in some meta-analyses; better evidence for chronic pain and neuropathy. Higher discontinuation-syndrome risk.

Bupropion (Wellbutrin, 1985 then 1989). Norepinephrine and dopamine reuptake inhibitor. Particularly useful where SSRIs cause sexual dysfunction or weight gain (bupropion does neither). Lower seizure threshold; contraindicated in seizure disorders and bulimia.

Mirtazapine (Remeron, 1996). Atypical mechanism (alpha-2 antagonism). Sedating; tends to increase appetite. Useful where insomnia and weight loss accompany depression.

Tricyclics (TCAs). Imipramine (1957), amitriptyline (1961), and a dozen others. The pre-SSRI standard. Slightly more effective than SSRIs for severe depression but with greater anticholinergic side effects, cardiotoxicity in overdose, and lethal narrow therapeutic index.

MAOIs. Phenelzine, tranylcypromine. Effective for atypical and treatment-resistant depression but require dietary tyramine restriction (hypertensive crisis risk). Rarely first-line.

Chapter XIThe mood stabiliser.

John Cade, Australian psychiatrist working at Bundoora Repatriation Mental Hospital outside Melbourne, published "Lithium Salts in the Treatment of Psychotic Excitement" in Medical Journal of Australia in September 1949. He had injected guinea pigs with lithium urate and noticed they became docile; he then trialled lithium carbonate in ten manic patients with dramatic effect.

Lithium is the gold-standard treatment for bipolar disorder. Effect sizes are larger than for any antidepressant in any condition. Lithium reduces suicide rates in bipolar patients by ~60% (the only psychotropic with a robust suicide-reduction signal). Long-term continuous lithium associates with reduced all-cause mortality in bipolar disorder.

The downsides limit its use. Narrow therapeutic index — toxicity above 1.5 mEq/L; lithium serum levels must be monitored. Renal effects with long-term use; ~20% develop nephrogenic diabetes insipidus; rare cases of chronic kidney disease. Thyroid suppression. Weight gain. Tremor.

The mechanism remains incompletely understood — lithium affects multiple intracellular signalling pathways (GSK-3, inositol monophosphatase). The "lithium response" is partly heritable; family history of lithium response is the best clinical predictor.

Chapter XIIThe neuroleptic story.

Chlorpromazine (Thorazine), synthesised at Rhône-Poulenc by Paul Charpentier in 1950, was tested in psychotic patients by Henri Laborit, Pierre Deniker, and Jean Delay at Sainte-Anne Hospital in 1952. The transformative effect on schizophrenia symptoms emptied the asylums of the post-war era within a decade.

The first-generation antipsychotics (haloperidol, fluphenazine, others) were dopamine D2 antagonists. Effective for positive symptoms (hallucinations, delusions) but with major motor side effects: parkinsonism, akathisia, tardive dyskinesia (the latter often irreversible).

The atypical (second-generation) antipsychotics — clozapine (revived in 1989 after a 1975 withdrawal for agranulocytosis), risperidone, olanzapine, quetiapine, aripiprazole, others — added serotonin 5-HT2A antagonism. Lower motor side effects but higher metabolic burden: weight gain, dyslipidaemia, type-2 diabetes. The CATIE trial (2005) found atypicals were not clearly superior to first-generation perphenazine.

Clozapine remains the most effective antipsychotic, particularly for treatment-resistant schizophrenia. It also requires weekly-then-monthly white-cell monitoring for life because of the agranulocytosis risk (~0.8%).

Chapter XIIITherapy plus medication.

The treatment-allocation question for moderate-to-severe depression and anxiety: psychotherapy alone, medication alone, or both. The empirical answer is partially settled.

For mild depression, psychotherapy alone is roughly equivalent to medication and has lower relapse risk. For moderate depression, both are equivalent in acute response; combination treatment outperforms either alone in some trials but not all. For severe depression, combination is generally superior to either monotherapy.

For anxiety disorders, the picture varies by diagnosis. CBT alone is first-line for OCD, social anxiety, panic, and PTSD; medication is added when therapy is unavailable, declined, or insufficient. For generalised anxiety disorder, CBT and SSRI/SNRI are roughly equivalent.

For schizophrenia and bipolar disorder, medication is the foundation; psychotherapy (CBT-p, family-focused therapy, IPSRT for bipolar) is adjunctive and improves functional outcomes.

The relative-cost calculation matters. Therapy is more expensive per session but typically time-limited; medication is cheaper short-term but often continued long-term. Patient preference is a strong predictor of adherence and should influence allocation.

Chapter XIVThe placebo problem.

The placebo response in mental health trials is large. For major depression, placebo response rates of 30–40% are typical; for anxiety, similar. The Kirsch meta-analyses (2002, 2008) argued the difference between antidepressant and placebo is clinically meaningful only in severe depression. The Cipriani 2018 reanalysis pushed back; antidepressants outperform placebo across severity, but the absolute difference is small in mild-moderate cases.

The implications. Many people who take antidepressants would have improved on placebo. The treatment effect is real but smaller than headlines or marketing suggest. The clinical decision is not "drug or no drug" but "drug plus the time, expectation, monitoring, and connection that come with starting one" vs the alternative.

The 2024 Cuijpers et al. meta-analysis on psychotherapy showed similar placebo issues — the gap between active therapy and "supportive control" is smaller than between active therapy and "no treatment / waitlist." The non-specific factors (therapeutic alliance, expectation, hope) account for a substantial fraction of the effect.

None of this means treatments don't work. It means they work less than the marketing claims and more than the skeptical reductions suggest.

Chapter XVPTSD treatment.

Three trauma-focused therapies have the strongest evidence for PTSD: prolonged exposure (PE; Edna Foa, late 1980s), cognitive processing therapy (CPT; Patricia Resick, 1992), and EMDR. All produce response rates of 50–70% in major trials and outperform medications and supportive therapy.

The shared mechanism is the engagement with the traumatic memory rather than its avoidance. The therapeutic logic — counter to the patient's natural impulse to avoid — is that controlled, structured re-engagement allows the memory to be processed, reorganised, and integrated rather than remaining in its raw, intrusive form.

Pharmacotherapy for PTSD is supportive but not curative. Sertraline and paroxetine have FDA approval; effect sizes are modest. Prazosin reduces nightmares. Benzodiazepines should be avoided — they impair fear extinction and prolong PTSD.

The 2020s development. MDMA-assisted therapy for PTSD; the Phase 3 trials by MAPS (now Lykos Therapeutics) showed substantial efficacy, but the FDA rejected the 2024 NDA, citing trial-design and conduct concerns. The clinical jury remains out; further trials are pending.

Chapter XVIThe 2020s renaissance.

The "second wave" of psychedelic research began around 2006 with Roland Griffiths's Johns Hopkins psilocybin work. By 2020, multiple Phase 2 trials had demonstrated substantial effects of psilocybin-assisted therapy for treatment-resistant depression, alcohol use disorder, and end-of-life distress. The FDA granted "breakthrough therapy" designations to psilocybin (2018, COMPASS Pathways) and MDMA (2017, MAPS).

The model is psychotherapy, not psychopharmacology. Treatment typically involves preparation sessions, one or two dosing sessions (5–8 hours each, in a structured therapeutic setting), and integration sessions afterward. The drug is the catalyst; the therapeutic work happens around it.

The 2024 setbacks. The FDA rejected the MAPS MDMA NDA in August 2024. Australian and Canadian psilocybin programmes are operational. The clinical evidence remains promising but contested; the policy landscape is fast-evolving.

Chapter XVIIThe fast-acting outlier.

Ketamine, an NMDA-receptor antagonist used as a dissociative anaesthetic since 1970, was found in early-2000s research to produce rapid antidepressant effects — within hours rather than weeks — in treatment-resistant depression. The Berman 2000 study and subsequent NIMH work (Carlos Zarate Jr.) established the effect.

The 2019 FDA approval of intranasal esketamine (Spravato) for treatment-resistant depression formalised the clinical use. Off-label IV racemic ketamine clinics proliferated in the 2010s; questions about evidence quality, dose-frequency optimisation, and abuse potential remain.

The mechanism — rapid AMPA-receptor and BDNF-mediated synaptogenesis appears central — has reframed depression neurobiology. The "monoamine hypothesis" of depression that drove SSRI development through the 1990s now sits alongside synaptic-plasticity and neuroinflammation models.

The major 2020s research challenge: the antidepressant effect is real but typically transient (days to weeks). Repeated dosing produces mixed durability. The "psychedelic mechanism" — including the dissociative experience itself — vs the pure pharmacological effect remains debated. The 2025 trials of dissociative-blocking adjuncts (showing whether the trip is needed) are the next data point.

Chapter XVIIIThe brain-stimulation approaches.

Electroconvulsive therapy (ECT). Introduced by Cerletti and Bini in Rome in 1938. Despite its 20th-century reputation, ECT remains the single most effective treatment for severe depression — particularly with melancholic features, psychotic features, catatonia, or imminent suicidality. Response rates 60–80%. Memory side effects, particularly autobiographical memory loss for events around the treatment period, are the principal limitation. Modern bilateral and right-unilateral protocols at lower doses reduce the cognitive cost.

Transcranial magnetic stimulation (TMS). FDA-cleared 2008. Magnetic field stimulation of the dorsolateral prefrontal cortex. Effect sizes more modest than ECT but no anaesthesia, no memory effects. Course of 20–36 sessions over 6 weeks. Response rates ~40–50% in treatment-resistant depression.

Deep brain stimulation (DBS). Implanted electrodes; Helen Mayberg's subcallosal cingulate work in the 2000s. Investigational for severe treatment-resistant depression and OCD. Persistent technical and selection challenges; not standard clinical care.

Chapter XIXChildren and adolescents.

The empirical base for children's mental-health treatment is smaller and rougher than for adults. The high-confidence findings:

CBT and IPT-A work for adolescent depression and anxiety; effect sizes comparable to or smaller than adult equivalents.

Family-based treatment (FBT) is first-line for adolescent anorexia nervosa. The Lock et al. RCTs and the Maudsley protocol gave the field its operational treatment of choice.

Stimulant medications (methylphenidate, amphetamine salts) for ADHD have large effect sizes (Cohen's d ~0.8–1.0) — among the largest in any psychiatric treatment. The MTA study (1999) established stimulant efficacy. The 2022 Catalá-López meta-analysis on long-term outcomes is more equivocal but the short-term symptomatic benefit is well-established.

SSRIs in adolescents and children carry the FDA black-box warning on suicidal ideation (2004). The TADS trial (2004) found fluoxetine plus CBT outperformed either alone for adolescent depression. Practice has settled toward SSRI use for moderate-severe adolescent depression with active suicidal-ideation monitoring.

Chapter XXSpecific to suicide.

Suicidality requires its own treatment focus, beyond the underlying depression or psychiatric condition.

The high-evidence suicide-specific interventions: Safety Planning Intervention (Stanley & Brown, 2012) — collaborative development of a written plan of warning signs, coping strategies, social contacts, and means restriction. Cognitive Therapy for Suicide Prevention (CT-SP) — a 10-session manualised therapy targeting suicidal cognition; reduced reattempt rates 50% in the Brown et al. 2005 trial. DBT — the only therapy with multiple RCTs showing reduction in completed suicides (in BPD populations).

The pharmacological literature: lithium reduces suicide in bipolar disorder; clozapine reduces suicide in schizophrenia; the antidepressant effect on suicide is small and equivocal.

The strongest non-clinical lever: means restriction. Restricting access to lethal means (firearms, particular medications, particular jumping points) substantially reduces suicide deaths. The classic case is the UK switch from coal gas to natural gas in the 1960s and 1970s, which collapsed gas-suicide rates without substantial substitution.

Chapter XXIThe treatment-resistant.

Eating disorders carry the highest mortality of any psychiatric diagnosis — anorexia nervosa with mortality rates ~5–10% in long-term follow-up.

For adolescent anorexia, family-based treatment (Maudsley FBT) is first-line and outperforms individual therapy. For adult anorexia, the empirical picture is bleaker — no treatment has demonstrated superiority over treatment as usual in well-controlled trials. The CBT-E (enhanced cognitive-behavioural therapy; Christopher Fairburn, Oxford), MANTRA, and SSCM (specialist supportive clinical management) approaches are roughly equivalent.

For bulimia nervosa and binge-eating disorder, CBT-E is the first-line treatment with the strongest evidence. Adapted protocols have substantially higher response rates than for anorexia.

Pharmacotherapy plays a supporting role. Fluoxetine has FDA approval for bulimia. Lisdexamfetamine (Vyvanse) has approval for binge-eating disorder. Olanzapine has limited evidence for weight restoration in anorexia.

The treatment-resistance, particularly in chronic adult anorexia, is one of the most painful gaps in psychiatric medicine.

Chapter XXIIAddiction.

Substance use disorders are mental health disorders that have become increasingly integrated into the mental-health treatment system in the 21st century. The strongest treatments combine pharmacotherapy with behavioural intervention.

Opioid use disorder. Methadone, buprenorphine, naltrexone are the FDA-approved medications. Buprenorphine (especially as office-based prescribing since 2002) has expanded substantially. Effect sizes are large — methadone reduces all-cause mortality in opioid-dependent patients by ~50%. The 2014–2024 fentanyl crisis has reshaped the field.

Alcohol use disorder. Naltrexone, acamprosate, and disulfiram are FDA-approved. Effects are real but modest. Behavioural interventions — MET (motivational enhancement therapy), CBT, 12-step facilitation — are roughly equivalent to one another, the COMBINE study (2006) found.

Tobacco. Varenicline, bupropion, and nicotine replacement therapy combined with behavioural support produce 20–30% one-year quit rates — substantially better than unaided cessation.

Stimulants. No FDA-approved pharmacotherapy. Contingency management (rewarding negative drug tests) has the strongest behavioural evidence base; remains underused.

Chapter XXIIIDigital therapeutics.

The 2010s and 2020s saw the rise of digital interventions: app-delivered CBT, online therapist-supported programmes, AI-assisted symptom tracking, and the contested case of conversational-AI "therapists."

iCBT — internet-delivered CBT, typically therapist-supported. The Andersson et al. and Hedman et al. work shows iCBT for depression and anxiety produces effect sizes comparable to face-to-face CBT, at substantially lower cost. The 2017 NICE guidance and the UK IAPT (now NHS Talking Therapies) programme deploy iCBT at population scale.

Self-guided apps. Headspace, Calm, Woebot, Wysa, and dozens of others. Effect sizes are smaller than therapist-supported variants — substantial dropout, modest engagement. Useful for low-severity, motivated users; insufficient for moderate-severe disorders.

AI-conversational systems. The 2024–2025 landscape is rapidly evolving and clinically uncertain. Early evidence on supervised systems (Therabot, Limbic) shows promise; the unsupervised commercial chatbot landscape carries documented risks (parasocial dependency, validation of suicidal ideation in some cases). Regulatory frameworks lag the deployment.

Chapter XXIVFinding a therapist.

The empirical literature on what to look for, distilled.

Modality matters less than the public assumes. The "common factors" research — Wampold, Norcross — shows that across modalities, ~60% of outcome variance is shared (therapeutic alliance, therapist qualities, expectation, hope) and only ~10% is specific to the technique. A skilled CBT therapist and a skilled psychodynamic therapist produce comparable outcomes for most patients with most disorders.

Therapist effects are large. Within any modality, therapist-to-therapist variance in outcomes is substantial. Some therapists consistently produce better outcomes than others; the evidence base for what predicts this is thin.

Match matters. Patient-therapist demographic match (race, gender, sexual orientation) shows mixed effects — small in most studies, larger in certain populations. Therapeutic alliance — the patient-rated quality of the working relationship — is a stronger predictor than match.

Stop and switch if not improving. The Lambert outcome-monitoring research showed routine outcome measurement (PHQ-9, GAD-7) and feedback to therapists improved outcomes substantially. If 4–6 sessions in there's no movement, change something — therapist, modality, or augment with medication.

Chapter XXVFrontiers.

Psychedelics. Psilocybin and MDMA, and possibly LSD and ibogaine. Regulatory landscape uncertain post-2024 FDA decision. Clinical case continues to develop.

Ketamine and rapid-acting antidepressants. Esketamine in clinical use; next-generation NMDA-modulators (rapastinel-class) in trials. The "psychoplastogen" framing — drugs that induce neuroplasticity — is the emerging mechanistic frame.

Inflammation-targeted. The 20-year inflammatory-depression hypothesis has produced trials of TNF-alpha antagonists (infliximab) and other anti-inflammatory drugs. Mixed but suggestive results, particularly in subgroups with elevated inflammatory markers.

Neuromodulation refinements. Stanford's SAINT protocol (accelerated TMS, FDA-cleared 2022) compresses TMS to 5 days. Closed-loop DBS systems for depression and OCD.

Precision psychiatry. Pharmacogenomics (CYP450 testing for SSRI metabolism) is mainstream but its impact on outcomes is debated. EEG-based and fMRI-based stratification for treatment selection remains research, not clinical care.

Chapter XXVITwenty essentials.

• 1949Lithium Salts in the Treatment of Psychotic ExcitementCade
• 1967Depression: Causes and TreatmentBeck
• 1979Cognitive Therapy of DepressionBeck et al.
• 1984Interpersonal Psychotherapy of DepressionKlerman & Weissman
• 1993Cognitive-Behavioral Treatment of Borderline Personality DisorderLinehan
• 1997An Unquiet MindJamison
• 1999The Multimodal Treatment of ADHD (MTA)MTA Cooperative Group
• 2001Treatment of Adolescent Anorexia NervosaLock & Le Grange
• 2007The Great Psychotherapy DebateWampold
• 2008Initial Severity and Antidepressant BenefitsKirsch et al.
• 2008Acceptance and Commitment TherapyHayes et al.
• 2014The Body Keeps the Scorevan der Kolk
• 2015Lost Connections (re-evaluation)Hari (popular)
• 2016Cognitive Behavior Therapy and Eating DisordersFairburn
• 2018Comparative Efficacy of 21 AntidepressantsCipriani et al. (Lancet)
• 2018How to Change Your MindPollan
• 2019NICE Depression in Adults GuidanceNICE
• 2020HealingInsel
• 2022Psilocybin for Treatment-Resistant Depression (NEJM)Goodwin et al.
• 2024Treating Depression: Updated APA GuidelineAPA

Chapter XXVIIWatch & read.

↑ What is Cognitive Behavioural Therapy?

More on YouTube

Watch · SSRI antidepressants · selective serotonin reuptake inhibitors
Watch · What is EMDR therapy? · Trauma therapy explained